Ocumension Therapeutics

About:

Ocumension Therapeutics is a pharmaceutical platform dedicated to identifying, developing, and commercializing ophthalmic therapies.

Website: https://www.ocumension.com/en/

Top Investors: Alcon, General Atlantic, Octagon Capital Advisors

Description:

Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first- or best-in-class ophthalmic therapies. The company’s vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. Since the inception, Ocumension Therapeutics has focused on building a platform integrating specialized capabilities in each major functionality involved in an ophthalmic drug's development cycle, from research and development, manufacturing to commercialization. Ocumension Therapeutics believes its platform positions it well to achieve leadership in China ophthalmology, with a first-mover advantage over future competitors.

Total Funding Amount:

$364M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Shanghai, Shanghai, China

Founded Date:

2017-01-01

Contact Email:

info(AT)ocumension.com

Founders:

Number of Employees:

251-500

Last Funding Date:

2024-08-12

IPO Status:

Public

© 2025 bioDAO.ai